Serum pro-inflammatory cytokines may play an important role in the association between periodontal disease and hyperlipidaemia.

The combination of the periodontal therapy and antilipemic treatment may provide beneficial effects on the metabolic and inflammatory control of hyperlipidemia.

Systemic and local MDA levels are increased by smoking in addition to the impact of periodontitis. The decreased local SOD, GSH-Px, and CAT activities observed in periodontitis patients may increase with smoking.

Improved periodontal health may influence metabolic control of hyperlipidemia and could be considered as an adjunct to the standard measures of hyperlipidemic patient care.

In this study, serum MDA and 8-OHdG were found to be highest in the HLp group. The increased levels of MDA and 8-OHdG in HLp patients may be a result of a harmful oxidative status in association with hyperlipidemia and periodontitis.

No abstract

NSPT decreased oxidative stress and the inflammatory status of patients with MetS and chronic periodontitis. Although similar periodontal improvements were achieved in both groups, the decreases in levels of hs-CRP and IL-6 in the MetS group did not reach the levels in the SH group. Based on these results, NSPT could be more effective in the control of systemic inflammation in patients with MetS in the short-term.

The IL-11/IL-17 ratio was decreased in the GAgP group because of the decreased IL-11 levels. The IL-11/IL-17 axis and the link between IL-17 and neutrophil function disorders in AgP should be investigated to clarify the role of the IL-11/IL-17 axis and its balance and imbalance in the pathogenesis of AgP.